Medication Misconceptions I

Friday, February 7, 2020 - 11:00-12:15 pm
UAN: 0107-9999-20-027-L01-P
0.125 CEU/1.25 hr
This course offers brief presentations on topics where recent practice has changed or study findings have challenged what was once considered “standard of care”. Discover why ARBs may not be safe in patients with ACE-inhibitor induced angioedema, how to prioritize latent tuberculosis therapy and more in this impactful session. 
Learning Objectives
Upon successful completion of this application-based CPE activity, participants should be able to:

1. Describe the relative risk of angioedema secondary to ARBs in patients with a prior history of ACE-inhibitor induced angioedema.
2. Discuss the reasons for the CDC's change in prioritization for latent tuberculosis therapy.
3. Explain why to avoid drugs we use for no reason.
4. Assess the safety of anticoagulation in the perioperative period.

Joseph Berendse
Joseph Berendse, PharmD, BCPS

Assistant Professor of Pharmacy Practice
South Dakota State University
Rapid City, SD

Chrystian Pereira

Chrystian Pereira, PharmD, BCPS

Associate Professor 
University of Minnesota
Saint Paul, MN

James Ray

James Ray, PharmD, CPE

Clinical Associate Professor
University of Iowa College of Pharmacy
Iowa City, IA

Lynn Kassel

Lynn Kassel, PharmD, BCPS

Associate Professor of Clinical Sciences
Drake University College of Pharmacy & Health Sciences
Des Moines, IA